Trade Name: Portrazza™
Necitumumab is the generic name for the trade name drug Portrazza™.
In some cases, health care professionals may use the trade name Portrazza™ when referring to the generic drug name necitumumab.

Drug type: Necitumumab is classified as a "monoclonal antibody" and "signal transduction inhibitor" by binding to epidermal growth factor receptors (EGFR). (For more detail, see "How Necitumumab Works" section below).

What Necitumumab Is Used For :
  • Indicated, in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non-small cell lung cancer.

Note: If a drug has been approved for one use, physicians may elect to use this same drug for other problems if they believe it may be helpful.

How Necitumumab Is Given :
  • Necitumumab is given through an infusion into a vein (intravenous, IV).
  • Necitumumab is administered over 60 minutes on Days 1 and 8 of each 3-week cycle prior to gemcitabine and cisplatin infusion.
  • The amount of necitumumab that you will receive depends on many factors, including you height and weight, your general health or other health problems, and the type of cancer or condition being treated. Your doctor will determine your dose and schedule.